Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its fourth quarter and full year 2011 financial results on Tuesday, February 21, 2012, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.

On Wednesday, February 22, 2012, at 9 a.m. ET, Furiex will conduct a live conference call and audio webcast to discuss financial results and product portfolio. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in:       +1 877 267 0934 (U.S./Canada)
+1 706 643 0961 (International)
Conference ID: 45542437

All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at www.furiex.com. The webcast will be archived shortly after the call for on-demand replay.

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of internal and partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner. Development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and two products on the market. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.

Furiex Pharmaceuticals, Inc.
Sailash Patel, 919-456-7814
sailash.patel@furiex.com